NCT04840394 - Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

September 30, 2024

Conditions

Tumor, Solid

Interventions

DRUG

BDB018

BDB018 is an immunotherapy agent.

DRUG

Pembrolizumab

Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.

Trial Locations (3)

34230

Florida Cancer Specialists, Sarasota

49501

START MidWest, Grand Rapids

78229

START, San Antonio